Registro de fonte primária
Nível de decisãoResultados topline
Monte Rosa Therapeutics Reports Positive GFORCE-1 Phase 1 Topline for MRT-8102 in ASCVD Risk Subjects
MRT-8102 achieved robust NEK7 degradation and normalized multiple key ASCVD pathogenic drivers (DAMPs, IL-1β, hsCRP, fibrinogen, Lp(a)) to healthy-volunteer levels in obese subjects with elevated CVD risk. The asset was safe and well-tolerated with no SAEs or increased infection risk. This topline outcome informs dose selection and enables planned Phase 2 starts in coronary artery disease (GFORCE-2, H1 2027), gout (GEMINI-1, Q4 2026/Q1 2027), and hidradenitis suppurativa (GALAXY-1, H1 2027).
Fatos principais
- Arquivado
- 1 de out. de 2026, 11:38
- Evento
- Resultados topline
- Direção
- Positivo
- Empresa
GLUEMonte Rosa- Ativo
- MRT-8102
- Fonte
- SEC 8-K
- Confiança
- Com fonte
- Redução de SAA
- 51%
- Redução de IL-6
- 54%
- Redução de HMGB1
- 40% (quartil superior)
- Redução de IL-1b
- 37% (quartil superior)
- Redução de hsCRP
- 85%
- Degradação de NEK7
- redução mediana de 80-90%
- Redução de S100A12
- 46%
- Redução de fibrinogénio
- 28%
- Redução de calprotectina
- 56%
- Redução de lipoproteína a
- 24%
Trecho da fonte
EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses HMGB1, calprotectin, S100A12, and SAA, damage-associated mol